SARS-CoV-2, the virus behind COVID-19, presented a unique challenge for molecular testing. Its fragile RNA genome is encased within a lipid envelope and often trapped in complex respiratory material rich in mucus, salts, and enzymes that rapidly degrade nucleic acids limiting true point-of-care testing in terms of limit of detection at low LODs. Extraction always add complexity to the system to remove inhibitors whilst maintaining sufficient copy numbers.

That’s why we built GoCollect®. Our proprietary reagent enables direct-to-amplification sample preparation, eliminating the need for dedicated extraction or laboratory infrastructure.

GoCollect® uniquely collects a precise and defined amount of saliva or nasal exudate. Then, the clever part, biosafe lysing agent breaks open the virus and protects the extracted nucleic acids against RNAase, all within the same single collection step. The RNA is immediately compatible with RT-LAMP or RT-PCR detection formats used in both portable and bench top POCT systems. GoCollect® also works with other viruses and bacteria, and with lateral flow tests, improving the amount of virus thats put onto the lateral flow strip.

More than a reagent, GoCollect® is a collection-and-stabilisation platform, preserving DNA and RNA at ambient temperature for days and weeks allowing accurate testing in clinics, emergency wards, drive-through stations, and mobile units without refrigeration or cold-chain logistics.

Simple. Reliable. POCT-ready.

With GoCollect® molecular testing can finally happen where it’s needed most, at the point of care.